RCM
CTMX icon

Raleigh Capital Management’s CytomX Therapeutics CTMX Stock Holding History

Raleigh Capital Management’s Portfolio CTMX Stock Details CTMX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-250
Closed -$258 – 673
2024
Q4 		$258 Hold
250
– – ﹤0.01% 976
2024
Q3 		$295 Hold
250
– – ﹤0.01% 950
2024
Q2 		$305 Hold
250
– – ﹤0.01% 937
2024
Q1 		$545 Hold
250
– – ﹤0.01% 878
2023
Q4 		$388 Hold
250
– – ﹤0.01% 1005
2023
Q3 		$323 Hold
250
– – ﹤0.01% 908
2023
Q2 		$430 Hold
250
– – ﹤0.01% 793
2023
Q1 		$378 Hold
250
– – ﹤0.01% 813
2022
Q4 		$400 Hold
250
– – ﹤0.01% 738
2022
Q3 		$0 Hold
250
– – ﹤0.01% 799
2022
Q2 		$0 Hold
250
– – ﹤0.01% 611
2022
Q1 		$1K Buy
+250
New +$960 ﹤0.01% 557

Other funds holding CTMX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
LCM
Laurion Capital Management New York $2.29B AUM 75.73% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Raleigh Capital Management's CTMX Position: Q1 2025 in Review

Raleigh Capital Management sold out of CytomX Therapeutics (CTMX) in Q1 2025, closing a stake of 250 shares — an estimated $258 sold.

Raleigh Capital Management first reported a position in CTMX in Q1 2022 and held it in 12 quarters. The position peaked at $1K in Q1 2022. 66 funds tracked by Wall St. Rank hold CTMX as of Q1 2025.

  • Raleigh Capital Management reported no remaining CytomX Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Raleigh Capital Management sold 250 CytomX Therapeutics shares in Q1 2025, an estimated $258.
  • Raleigh Capital Management first reported a position in CytomX Therapeutics in Q1 2022 and held it in 12 quarters.
  • Raleigh Capital Management's CytomX Therapeutics position peaked at $1K in Q1 2022.
  • 66 funds tracked by Wall St. Rank held CytomX Therapeutics as of Q1 2025.

Based on Raleigh Capital Management's 13F filing for Q1 2025, filed 29 Apr 2025.